ClinicalTrials.gg
CompletedNCT00421122Updated Mar 27, 2009

Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD

A Phase 3 interventional study of budesonide/formoterol (Symbicort) and budesonide (Pulmicort) in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 8 sites in China. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2009-03-27.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
315
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. Budesonide · Pulmonary Disease, Chronic Obstructive.

Enrollment
11th of 43
315 · median 99
Started
2006
with 2 others
Phase 3
15 of 43
1 open now
Registered
4th of 43
by date
Lead sponsor
10 of 43
AstraZeneca

Among the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, this one is the 11th largest by enrollment, is one of 3 that started in 2006, is one of 15 in phase 3, and was the 4th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This study aims at evaluating efficacy and safety of Symbicort® Turbuhaler® in Chinese COPD patients as defined by GOLD treatment guidelines in order to obtain an approval for indication of COPD from Chinese State Food and Drug Administration.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Chinese patients
  • COPD
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated inform consent
  • Out-patient, clinical diagnosis of
  • Men or women at the age of 40 or over

Exclusion criteria

Exclusion Criteria:

  • A history of asthma
  • Seasonal allergic rhinitis before 40 years of age
  • Patients with significant or unstable ischemic heart disease, arrhythmia, cardiomyopathy, heart failure, uncontrolled hypertension as defined by the investigator or other disorder
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
315 participants (actual)

Study arms

  • Active comparator
    1

    Bricasol®

    Drug: terbutaline sulfate (Bricasol)

  • Experimental
    2

    Bricasol® + Pulmicort®

    Drug: budesonide (Pulmicort) · Drug: terbutaline sulfate (Bricasol)

  • Experimental
    3

    Bricasol® + Symbicort®

    Drug: budesonide/formoterol (Symbicort) · Drug: terbutaline sulfate (Bricasol)

Interventions

06

What researchers measure

Primary outcomes

  1. Post-study medication FEV1

    Time frame: 1 hour after medication

Secondary outcomes

  1. FVC

    Time frame: Pre dose and 1 hour post dose

  2. FEV1

    Time frame: Pre-dose and 15 minutes post dose

  3. SGRQ symptom scores

  4. COPD symptom scores

  5. morning and evening PEF

    Time frame: Assessed daily

  6. reliever medication use

  7. AE

  8. lab measures

  9. ECG

  10. physician examination

  11. vital signs

07

Study locations

8 sites
  • Research Site
    Beijing, Beijing, China
  • Research Site
    Guangzhou, Guangdong, China
  • Research Site
    Nanjing, Jiangsu, China
  • Research Site
    Shenyang, Liaoling, China
  • Research Site
    Shanghai, Shanghai, China
  • Research Site
    Xi'an, Shanxi, China
  • Research Site
    Chengdu, Sichuan, China
  • Research Site
    Hangzhou, Zhejiang, China
08

References and documents

Publications

  • Zhong N, Zheng J, Wen F, Yang L, Chen P, Xiu Q, Yao W, Sun T, Zhao Z, Shen H, Shi Y, Lin J, Li Q. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Curr Med Res Opin. 2012 Feb;28(2):257-65. doi: 10.1185/03007995.2011.636420. Epub 2012 Jan 20. PubMed 22046961 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2006 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2007
First posted
Jan 11, 2007
Start
Sep 2006
CompletionActual
Nov 2007
Last update
Mar 27, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00421122
Lead sponsor
AstraZeneca
First posted
Jan 11, 2007
Start date
Sep 2006
Completion
Nov 2007
Last update
Mar 27, 2009

Study contacts

Symbicort Medical Science Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion